I 102. uge var 49 patienter stadig på infliximabbehandling, og blandt disse var 30 (61%) BASDAI 50 responders.
At 102 weeks there were 49 subjects still on infliximab treatment and among those, 30 (61%) were BASDAI 50 responders.